Trial · NCT00918385
Adverse events327
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 327
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Arm 1=High AR Nilutamide | 1 | 14 | |
| other | Anemia | Blood and lymphatic system disorders | Arm 2= Low AR Dasatinib | 1 | 17 | |
| other | Anemia | Blood and lymphatic system disorders | Combination Nilutamide and Dasatinib | 0 | 23 | |
| other | Dizziness | Nervous system disorders | Arm 1=High AR Nilutamide | 1 | 14 | |
| other | Dizziness | Nervous system disorders | Arm 2= Low AR Dasatinib | 0 | 17 | |
| other | Dizziness | Nervous system disorders | Combination Nilutamide and Dasatinib | 0 | 23 | |
| other | Obstruction, GU:Ureter | Renal and urinary disorders | Arm 1=High AR Nilutamide | 1 | 14 | |
| other | Obstruction, GU:Ureter | Renal and urinary disorders | Arm 2= Low AR Dasatinib | 0 | 17 | |
| other | Obstruction, GU:Ureter | Renal and urinary disorders | Combination Nilutamide and Dasatinib | 0 | 23 | |
| other | Eye disorders - Other | Eye disorders | Arm 1=High AR Nilutamide | 0 | 14 | |
| other | Eye disorders - Other | Eye disorders | Arm 2= Low AR Dasatinib | 0 | 17 | |
| other | Eye disorders - Other | Eye disorders | Combination Nilutamide and Dasatinib | 1 | 23 | |
| serious | Anemia | Blood and lymphatic system disorders | Arm 1=High AR Nilutamide | 11 | 14 | |
| serious | Anemia | Blood and lymphatic system disorders | Arm 2= Low AR Dasatinib | 11 | 17 | |
| serious | Anemia | Blood and lymphatic system disorders | Combination Nilutamide and Dasatinib | 13 | 23 | |
| serious | Lymph node pain | Blood and lymphatic system disorders | Arm 1=High AR Nilutamide | 1 | 14 | |
| serious | Lymph node pain | Blood and lymphatic system disorders | Arm 2= Low AR Dasatinib | 0 | 17 | |
| serious | Lymph node pain | Blood and lymphatic system disorders | Combination Nilutamide and Dasatinib | 0 | 23 | |
| serious | Ear and labyrinth disorders - Other | Ear and labyrinth disorders | Arm 1=High AR Nilutamide | 0 | 14 | |
| serious | Ear and labyrinth disorders - Other | Ear and labyrinth disorders | Arm 2= Low AR Dasatinib | 1 | 17 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00918385/events